Magic mushroom compound takes on PTSD in major new trial
NCT ID NCT07570654
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether COMP360, a lab-made psilocybin, can reduce PTSD symptoms when given with professional support. About 300 adults with PTSD will receive either a high or low dose and be followed for 8 weeks. The goal is to see if the drug safely eases symptoms like flashbacks and anxiety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- COMP360 psilocybin (a lab-made form of the active compound in magic mushrooms)
- What this could lead to
- If it works, this could offer a new treatment option that reduces PTSD symptoms with just a few monitored sessions.
- What could go wrong
- This is still in testing; the lower dose control group may also show improvement, and psilocybin can cause temporary anxiety or confusion. Long-term benefits are not yet known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PTSD are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can six short writing sessions ease PTSD in underserved patients?
- Can a psychedelic compound help veterans and first responders with PTSD and alcohol use disorder?
- Faith-Based therapy aims to heal trauma in young women
- Could play be a lifeline for children of war? a major study investigates
- Brain scans may guide psychedelics and magnetic pulses to quell suicidal thoughts
- Can online training equip therapists to tackle PTSD and addiction?